Objective:to evaluate the quality of life of adult patients with hematological cancer
comparing Hematopoietic Stem Cell Transplantation modalities during the
first year of treatment. Method:this is an observational and longitudinal research with 55 participants. Data
collection was performed in six steps: before transplantation, pancytopenia,
before hospital discharge, after 100, 180 and 360 days, in a reference
hospital in Brazil for this treatment. The international instruments Quality
of Life Questionnaire - Core 30 and Functional Assessment Cancer Therapy -
Bone Marrow Transplantation were validated and translated into Portuguese
(Brazil). Results:the mean age of participants was 36 years, 65% (n = 36) had leukemia
diagnosis and 71% (n = 39) had undergone allogenic transplantation. In the
Quality of Life Questionnarie - Core30 instrument, the pain symptom was
significant between the first and second stages, and loss of appetite
between the third and fourth stages, both in the allogenic group. In the
Functional Assessment Cancer Therapy - Bone Marrow Transplantation, the
functional well-being domain was significant between the third and fourth
stages, also in the allogenic group. Conclusions:although the aggressiveness of treatment affects quality of life, patients
consider it satisfactory after the first year. There are few significant
differences between autologous and allogenic patients, and both groups have
recovered in the course of the process.